De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

PharmaResearch Toekomstige groei

Future criteriumcontroles 5/6

PharmaResearch zal naar verwachting groeien in winst en omzet met respectievelijk 22.2% en 22.1% per jaar. De winst per aandeel zal naar verwachting groeien met 21.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 21.3% zijn.

Belangrijke informatie

22.2%

Groei van de winst

21.7%

Groei van de winst per aandeel

Biotechs winstgroei	64.3%
Inkomstengroei	22.1%
Toekomstig rendement op eigen vermogen	21.3%
Dekking van analisten	Good
Laatst bijgewerkt	12 Sep 2024

Recente toekomstige groei-updates

Recent updates

PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Aug 15

Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today

May 21

PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Apr 09

Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Mar 23

Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Mar 05

Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Feb 17

Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

Feb 02

Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

Jan 20

Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Jan 07

Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

Dec 23

Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

Dec 08

Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Nov 25

Winst- en omzetgroeiprognoses

KOSDAQ:A214450 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (KRW Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	515,314	156,525	140,700	150,700	6
12/31/2025	414,966	128,640	112,600	124,183	7
12/31/2024	337,443	101,320	89,260	106,833	7
6/30/2024	296,594	90,744	76,811	104,279	N/A
3/31/2024	280,285	76,092	70,589	85,849	N/A
12/31/2023	261,011	76,551	52,260	64,945	N/A
9/30/2023	244,661	64,902	41,817	53,239	N/A
6/30/2023	222,030	55,615	43,861	57,280	N/A
3/31/2023	204,932	48,964	46,461	61,734	N/A
12/31/2022	194,759	40,577	41,686	59,404	N/A
9/30/2022	183,191	46,501	43,484	65,744	N/A
6/30/2022	175,719	42,366	42,071	65,573	N/A
3/31/2022	164,813	43,752	38,455	62,868	N/A
12/31/2021	154,083	46,689	41,866	65,297	N/A
9/30/2021	143,282	47,110	36,738	58,386	N/A
6/30/2021	133,706	41,534	7,076	45,944	N/A
3/31/2021	122,609	40,153	6,042	43,936	N/A
12/31/2020	108,746	32,774	-2,991	32,392	N/A
9/30/2020	101,282	27,003	-4,928	27,003	N/A
6/30/2020	91,747	23,109	13,967	23,521	N/A
3/31/2020	84,091	16,407	11,603	18,946	N/A
12/31/2019	83,872	16,667	9,489	19,272	N/A
9/30/2019	77,416	19,060	250	12,948	N/A
6/30/2019	73,324	16,384	-7,794	13,176	N/A
3/31/2019	70,242	15,310	-12,069	8,818	N/A
12/31/2018	64,281	14,408	-19,414	5,203	N/A
9/30/2018	61,865	6,913	-13,353	6,975	N/A
6/30/2018	60,777	11,134	-9,967	7,070	N/A
3/31/2018	56,519	12,579	N/A	5,562	N/A
12/31/2017	54,470	12,956	N/A	8,555	N/A
9/30/2017	50,615	14,522	N/A	8,312	N/A
6/30/2017	47,241	13,472	N/A	6,052	N/A
3/31/2017	46,580	14,378	N/A	7,680	N/A
12/31/2016	45,953	13,909	N/A	8,161	N/A
9/30/2016	45,092	16,725	N/A	10,507	N/A
12/31/2015	37,455	12,878	N/A	16,023	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei A214450 ( 22.2% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van A214450 ( 22.2% per jaar) zal naar verwachting langzamer groeien dan de markt KR ( 29.7% per jaar).

Hoge groeiwinsten: De winst van A214450 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van A214450 ( 22.1% per jaar) zal naar verwachting sneller groeien dan de markt KR ( 10.5% per jaar).

Hoge groei-inkomsten: De omzet van A214450 ( 22.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen A214450 zal naar verwachting over 3 jaar hoog zijn ( 21.3 %)

PharmaResearch Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 7.1% to ₩187,500

Price target increased by 19% to ₩158,750

Price target increased by 11% to ₩107,500

Price target decreased to ₩88,300

Consensus forecasts updated

Price target decreased to ₩96,500

Recent updates

PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

New minor risk - Share price stability

New minor risk - Shareholder dilution

Price target increased by 7.1% to ₩187,500

Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today

Investor sentiment improves as stock rises 18%

PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Full year 2023 earnings released: EPS: ₩7,571 (vs ₩4,067 in FY 2022)

Upcoming dividend of ₩660 per share at 0.6% yield

Price target increased by 19% to ₩158,750

Investor sentiment improves as stock rises 15%

Now 20% undervalued

New minor risk - Shareholder dilution

Now 20% undervalued

Price target increased by 11% to ₩107,500

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 20%

Now 21% undervalued

Price target decreased to ₩88,300

Upcoming dividend of ₩600 per share

Consensus forecasts updated

Price target decreased to ₩96,500

Price target decreased to ₩100,000

Consensus forecasts updated

Price target increased to ₩112,500

Upcoming dividend of ₩500 per share

PharmaResearch Co., Ltd. (KOSDAQ:A214450) acquired Medicoson Co., Ltd.

Price target increased to ₩120,000

Consensus revenue estimates increase to ₩152.8m

Price target increased to ₩88,100

Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

New 90-day high: ₩64,900

Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

New 90-day low: ₩53,900

Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

New 90-day low: ₩56,100

Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

New 90-day low: ₩57,600

Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Third quarter 2020 earnings released: EPS ₩812

Price target raised to ₩78,433

New 90-day high - ₩63,300

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven